Literature DB >> 18955806

Complete remission of unresectable colon cancer after preoperative chemotherapy selected by adenosine triphosphate-based chemotherapy response assay.

Jung Wook Huh1, Yoon Ah Park, Eun Joo Jung, Kang Young Lee, Ji Eun Kwon, Seung-Kook Sohn.   

Abstract

The adenosine triphosphate-based chemotherapy response assay (ATP-CRA) is a chemosensitivity test that offers the potential of selecting cancer treatments based on the responsiveness of individual tumors. We report a case of 47-yr-old male, presented with sigmoid colon cancer with multiple liver and peritoneal metastases, in which there was a complete response for the primary colon cancer after administration of preoperative chemotherapy selected by ATP-CRA. Oxaliplatin was the most sensitive drug based on the ATP-CRA where the specimen obtained by ultrasound- guided percutaneous liver biopsy was used. After twelve cycles of oxaliplatincapecitabine chemotherapy, abdominopelvic computed tomography revealed marked shrinkage of the liver metastases and positron emission tomography showed no uptake of 18F-fluoro-deoxy-glucose (FDG) either in the liver or peritoneum except localized uptake in the sigmoid colon. The patient underwent an anterior resection and radiofrequency ablation of the liver metastases, which resulted in a macroscopic curative resection of the cancer cells. Histological examination revealed no residual cancer cells in the resected specimen of the sigmoid colon. This result suggested that preoperative chemotherapy chosen by ATP-CRA may be useful for treating advanced colon cancer with unresectable liver and peritoneal metastases.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18955806      PMCID: PMC2579999          DOI: 10.3346/jkms.2008.23.5.916

Source DB:  PubMed          Journal:  J Korean Med Sci        ISSN: 1011-8934            Impact factor:   2.153


  11 in total

Review 1.  Review of the efficacy of individualized chemotherapy selected by in vitro drug sensitivity testing for patients with cancer.

Authors:  P Cortazar; B E Johnson
Journal:  J Clin Oncol       Date:  1999-05       Impact factor: 44.544

2.  Prospective assessment of primary rectal cancer response to preoperative radiation and chemotherapy using 18-fluorodeoxyglucose positron emission tomography.

Authors:  J G Guillem; J Puig-La Calle; T Akhurst; S Tickoo; L Ruo; B D Minsky; M J Gollub; D S Klimstra; M Mazumdar; P B Paty; H Macapinlac; H Yeung; L Saltz; R D Finn; Y Erdi; J Humm; A M Cohen; S Larson
Journal:  Dis Colon Rectum       Date:  2000-01       Impact factor: 4.585

3.  Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer.

Authors:  P Piedbois; P Rougier; M Buyse; J Pignon; L Ryan; R Hansen; B Zee; B Weinerman; J Pater; C Leichman; J Macdonald; J Benedetti; J Lokich; J Fryer; G Brufman; R Isacson; A Laplanche; E Levy
Journal:  J Clin Oncol       Date:  1998-01       Impact factor: 44.544

4.  Double cancer (lung and colon cancer) that showed complete remission with irinotecan and cisplatin combined chemotherapy.

Authors:  T Kaneki; T Koizumi; A Kawashima; K Tsushima; K Kubo; K Fujimoto; T Honda; T Akamatsu
Journal:  J Gastroenterol       Date:  2000       Impact factor: 7.527

5.  Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival.

Authors:  René Adam; Valérie Delvart; Gérard Pascal; Adrian Valeanu; Denis Castaing; Daniel Azoulay; Sylvie Giacchetti; Bernard Paule; Francis Kunstlinger; Odile Ghémard; Francis Levi; Henri Bismuth
Journal:  Ann Surg       Date:  2004-10       Impact factor: 12.969

6.  FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.

Authors:  Christophe Tournigand; Thierry André; Emmanuel Achille; Gérard Lledo; Michel Flesh; Dominique Mery-Mignard; Emmanuel Quinaux; Corinne Couteau; Marc Buyse; Gérard Ganem; Bruno Landi; Philippe Colin; Christophe Louvet; Aimery de Gramont
Journal:  J Clin Oncol       Date:  2003-12-02       Impact factor: 44.544

7.  A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.

Authors:  Richard M Goldberg; Daniel J Sargent; Roscoe F Morton; Charles S Fuchs; Ramesh K Ramanathan; Stephen K Williamson; Brian P Findlay; Henry C Pitot; Steven R Alberts
Journal:  J Clin Oncol       Date:  2003-12-09       Impact factor: 44.544

8.  Complete remission of primary colon cancer in a metastatic patient treated with CPT-11 plus capecitabine.

Authors:  G Brandi; M A Pantaleo; C Calabrese; M Di Battista; R Poggi; E Bajetta; G Biasco
Journal:  Int J Colorectal Dis       Date:  2004-06-08       Impact factor: 2.571

9.  Adenosine triphosphate-based chemotherapy response assay (ATP-CRA)-guided platinum-based 2-drug chemotherapy for unresectable nonsmall-cell lung cancer.

Authors:  Yong Wha Moon; Sung Ho Choi; Yong Tai Kim; Joo Hyuk Sohn; Joon Chang; Se Kyu Kim; Moo Suk Park; Kyung Young Chung; Hyoun Ju Lee; Joo-Hang Kim
Journal:  Cancer       Date:  2007-05-01       Impact factor: 6.860

10.  XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer.

Authors:  Jim Cassidy; Josep Tabernero; Chris Twelves; René Brunet; Charles Butts; Thierry Conroy; Filippo Debraud; Arie Figer; Johannes Grossmann; Noriaki Sawada; Patrick Schöffski; Alberto Sobrero; Eric Van Cutsem; Eduardo Díaz-Rubio
Journal:  J Clin Oncol       Date:  2004-06-01       Impact factor: 44.544

View more
  4 in total

Review 1.  Benefits of functional assays in personalized cancer medicine: more than just a proof-of-concept.

Authors:  Christophe Bounaix Morand du Puch; Mathieu Vanderstraete; Stéphanie Giraud; Christophe Lautrette; Niki Christou; Muriel Mathonnet
Journal:  Theranostics       Date:  2021-09-21       Impact factor: 11.556

2.  Heterogeneity of adenosine triphosphate-based chemotherapy response assay in colorectal cancer--secondary publication.

Authors:  Jung Wook Huh; Yoon Ah Park; Kang Young Lee; Seung-Kook Sohn
Journal:  Yonsei Med J       Date:  2009-10-21       Impact factor: 2.759

3.  Bone morphogenetic protein 7 is associated with the nodal invasion of colon cancer.

Authors:  Tianqi Zhang; Jining Fu; Yueting Li; Yaohui Wang; Long Zhang; Ying Liu
Journal:  Oncol Lett       Date:  2016-01-14       Impact factor: 2.967

4.  Clinical value of an adenosine triphosphate-based chemotherapy response assay in resectable stage III colorectal cancer.

Authors:  Chan Dong Kim; So Hyun Kim; Sang Hoon Jung; Jae Hwang Kim
Journal:  Ann Surg Treat Res       Date:  2019-07-29       Impact factor: 1.859

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.